Anti-tumor effects of toxins targeted to the prostate specific membrane antigen

Prostate

Volumn 53, Issue 1, 2002, Pages 9-23

  Fracasso, Giulio ^a   Bellisola, Giuseppe ^a,b   Cingarlini, Sara ^a   Castelletti, Deborah ^a   Prayer Galetti, Tommaso ^c   Pagano, Francesco ^c   Tridente, Giuseppe ^a   Colombatti, Marco ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Immunotherapy; Immunotoxins; Prostate carcinoma; Prostate specific membrane antigen; Ricin; Spheroids

Indexed keywords

IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY PEQ226.5; MONOCLONAL ANTIBODY PM2P079.1; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RICIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL COUNT; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DOSE RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR SPHEROID;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; BONE NEOPLASMS; CARBOXYPEPTIDASES; CARCINOMA; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOTOXINS; MALE; PROSTATIC NEOPLASMS; RICIN; TUMOR CELLS, CULTURED;

EID: 0037106034     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10117     Document Type: Article

References (58)

1. Prostate cancer: An overview of an increasing dilemma
2. National Cancer Institute roundtable on prostate cancer: Future research directions
3. Immunotoxins: An update
4. Immunotoxins in cancer therapy
5. Targeted toxins
6. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients
7. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: A novel folate hydrolase
8. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
9. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5
10. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissue
11. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids
12. Expression of the prostate-specific membrane antigen
13. Up-regulation of prostate-specific membrane antigen after androgen-deprivation therapy
14. Prostate-specific membrane antigen expression in normal and malignant human tissues
15. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
16. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
17. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer
18. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer
19. Constitutive and antibody-induced internalization of prostate-specific membrane antigen
20. Cytoreductive effects of anti-transferrin receptor immunotoxin in a multicellular tumor spheroid model
21. Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures
22. A simplified method for the production and growth of multicellular tumor spheroids
23. The attractions of proteins for small molecules and ions
24. Monoclonal antibody-ricin or ricin A chain hybrids: Kinetic analysis of cell killing for tumor therapy
25. Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores
26. A Gompertzian model of human breast cancer growth
27. Multiexponential, multicompartmental and non-compartmental modeling. II. Data analysis and statistical considerations
28. Influence of tumor growth kinetics on response to doxorubicin treatment of C3H mammary carcinoma
29. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line
30. pH and the recycling of transferrin during receptor-mediated endocytosis
31. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells
32. Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines
33. Sensitivity of human glioma cells to cytotoxic heteroconjugates
34. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591)
35. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo
36. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages
37. The removal of carbohydrates from ricin with endoglycosidases H, F, and D and alpha-mannosidase
38. Structures of sugar chains of ricin D
39. Cell surface and intracellular functions for ricin galactose binding
40. A comparative study of ricin and diphtheria toxin-antibody-conjugate kinetics on protein synthesis inactivation
41. Sensitivity of human leukemia cells in exponential or stationary growth phase to anti-CD5 immunotoxins. Role of intracellular processing events
42. Growth and characterization of LNCaP prostate cancer cell spheroids
43. Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin
44. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALA-Dase/folate hydrolase
45. Toxin entry: Retrograde transport through the secretory pathway
46. Carboxylic ionophores enhance the cytotoxic potency of ligand- and antibody-delivered ricin A chain
47. Carrier protein-monensin conjugates: Enhancement of immunotoxin cytotoxicity and potential in tumor treatment
48. Bone metastases: Improving the therapeutic index
49. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors
50. A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier
51. The pharmacology of monoclonal antibodies
52. Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T cells
53. Effect of therapeutic macromolecules in spheroids
54. The standard man in relation to internal radiation dose concepts
55. Advances in immunotoxin biology and therapy: A summary of the Fourth International Symposium on Immunotoxins
56. Bioactivities of ricin retained and its immunoreactivity to anti-ricin antibodies alleviated through pegylation
57. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer
58. The kinetics of antibody binding to membrane antigens in solution and at the cell surface